cladribine

Overview

Cladribine (2-chlorodeoxyadenosine, 2-CdA) is a deoxyadenosine analog that accumulates in cells with high deoxyadenosine kinase activity (particularly lymphoid and myeloid cells), where it is phosphorylated to its active triphosphate form, inhibiting DNA synthesis and repair. It is FDA-approved for hairy cell leukemia and is used in AML induction (often in the CLAG or CLAG-M regimen) and in relapsed/refractory disease.

Evidence in the corpus

• Referenced as part of salvage or induction regimens for relapsed/refractory AML in the context of the WashU decitabine trial (NCT01687400, N=116); cladribine-containing regimens are described as prior treatments in some relapsed-AML extension-cohort patients from the University of Chicago (2005–2010) PMID:27959731

Resistance mechanisms

• Not specifically reported in the corpus.

Cancer types (linked)

• AML — salvage/induction regimen component (CLAG, CLAG-M) in relapsed disease.

Sources

• PMID:27959731 — Welch et al. 2016, NEJM. WashU AML/MDS decitabine trial; cladribine referenced as prior salvage treatment in extension-cohort relapsed-AML patients.

This page was processed by crosslinker on 2026-05-14.